FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136145> ?p ?o ?g. }

• W4324136145 endingPage "715" @default.
• W4324136145 startingPage "715" @default.
• W4324136145 abstract "715 Background: Treatment response monitoring is key to effective disease management for patients with advanced (RCC) and can potentially improve clinical outcomes. Circulating tumor DNA (ctDNA) has shown promise as a biomarker in the early identification of treatment response in a variety of tumor types. Herein, we evaluated ctDNA-derived molecular residual disease (MRD) detection and dynamics in both clear cell (ccRCC) and non-clear cell (nccRCC) RCC patients treated with standard of care therapy and provide correlations with clinical outcomes. Methods: This was a multi-center retrospective analysis of real-world data obtained from commercial ctDNA testing (Signatera, Natera, Inc.), 41 patients (142 plasma samples) with high-risk resected or metastatic RCC were analyzed for ctDNA. Clinical data were collected on IMDC risk category, pathologic subtype, tumor stage and grade including the presence of sarcomatoid/rhabdoid features. Progression on radiological imaging was based on RECIST 1.1. criteria. Results: Of the 41 patients, 73% (30/41) had ccRCC and the remaining 27% (11/41) were nccRCC. Immunotherapy was administered as a single agent or in combination with other immune checkpoint inhibitor agents/targeted therapy in 78% (32/41) in either frontline or refractory settings. ctDNA detection at any time point was 70% (29/41) and patients were followed-up for a median of 26.4 weeks (range: 0.9-90.6) from the first ctDNA time point. Fourteen patients (34%) experienced disease progression during follow-up and all had ctDNA detected ahead of radiological progression (100% sensitivity) with a median lead time of 13.6 weeks (range: 1-39.7 weeks). Concordance between clinical outcome and ctDNA status (detected or not detected) was observed in 78% (32/41) of the patients, 12% (5/41) showed discordance, and imaging data is pending for 10% (4/41) at the time of analysis. Conclusions: Collectively, our study demonstrates high concordance between MRD status and subsequent clinical outcomes. MRD had 100% sensitivity for predicting subsequent radiographic progression with significant median lead time. MRD may serve as a valuable tool for monitoring patients on immunotherapy-based regimens for RCC." @default.
• W4324136145 created "2023-03-15" @default.
• W4324136145 creator A5003194406 @default.
• W4324136145 creator A5017312893 @default.
• W4324136145 creator A5020125488 @default.
• W4324136145 creator A5027858713 @default.
• W4324136145 creator A5032032184 @default.
• W4324136145 creator A5037957708 @default.
• W4324136145 creator A5038007660 @default.
• W4324136145 creator A5039350928 @default.
• W4324136145 creator A5047859811 @default.
• W4324136145 creator A5052820201 @default.
• W4324136145 creator A5059120761 @default.
• W4324136145 creator A5074080606 @default.
• W4324136145 creator A5075600831 @default.
• W4324136145 creator A5076269626 @default.
• W4324136145 date "2023-02-20" @default.
• W4324136145 modified "2023-10-04" @default.
• W4324136145 title "Longitudinal detection of circulating tumor DNA in patients with advanced renal cell carcinoma." @default.
• W4324136145 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.715" @default.
• W4324136145 hasPublicationYear "2023" @default.
• W4324136145 type Work @default.
• W4324136145 citedByCount "3" @default.
• W4324136145 countsByYear W43241361452023 @default.
• W4324136145 crossrefType "journal-article" @default.
• W4324136145 hasAuthorship W4324136145A5003194406 @default.
• W4324136145 hasAuthorship W4324136145A5017312893 @default.
• W4324136145 hasAuthorship W4324136145A5020125488 @default.
• W4324136145 hasAuthorship W4324136145A5027858713 @default.
• W4324136145 hasAuthorship W4324136145A5032032184 @default.
• W4324136145 hasAuthorship W4324136145A5037957708 @default.
• W4324136145 hasAuthorship W4324136145A5038007660 @default.
• W4324136145 hasAuthorship W4324136145A5039350928 @default.
• W4324136145 hasAuthorship W4324136145A5047859811 @default.
• W4324136145 hasAuthorship W4324136145A5052820201 @default.
• W4324136145 hasAuthorship W4324136145A5059120761 @default.
• W4324136145 hasAuthorship W4324136145A5074080606 @default.
• W4324136145 hasAuthorship W4324136145A5075600831 @default.
• W4324136145 hasAuthorship W4324136145A5076269626 @default.
• W4324136145 hasConcept C121332964 @default.
• W4324136145 hasConcept C121608353 @default.
• W4324136145 hasConcept C126322002 @default.
• W4324136145 hasConcept C142424586 @default.
• W4324136145 hasConcept C143998085 @default.
• W4324136145 hasConcept C146357865 @default.
• W4324136145 hasConcept C151730666 @default.
• W4324136145 hasConcept C185592680 @default.
• W4324136145 hasConcept C203092338 @default.
• W4324136145 hasConcept C2777472916 @default.
• W4324136145 hasConcept C2777701055 @default.
• W4324136145 hasConcept C2778822529 @default.
• W4324136145 hasConcept C2779134260 @default.
• W4324136145 hasConcept C2779984678 @default.
• W4324136145 hasConcept C2780073493 @default.
• W4324136145 hasConcept C2781197716 @default.
• W4324136145 hasConcept C2781278892 @default.
• W4324136145 hasConcept C2781335228 @default.
• W4324136145 hasConcept C535046627 @default.
• W4324136145 hasConcept C55493867 @default.
• W4324136145 hasConcept C71924100 @default.
• W4324136145 hasConcept C86803240 @default.
• W4324136145 hasConcept C87355193 @default.
• W4324136145 hasConceptScore W4324136145C121332964 @default.
• W4324136145 hasConceptScore W4324136145C121608353 @default.
• W4324136145 hasConceptScore W4324136145C126322002 @default.
• W4324136145 hasConceptScore W4324136145C142424586 @default.
• W4324136145 hasConceptScore W4324136145C143998085 @default.
• W4324136145 hasConceptScore W4324136145C146357865 @default.
• W4324136145 hasConceptScore W4324136145C151730666 @default.
• W4324136145 hasConceptScore W4324136145C185592680 @default.
• W4324136145 hasConceptScore W4324136145C203092338 @default.
• W4324136145 hasConceptScore W4324136145C2777472916 @default.
• W4324136145 hasConceptScore W4324136145C2777701055 @default.
• W4324136145 hasConceptScore W4324136145C2778822529 @default.
• W4324136145 hasConceptScore W4324136145C2779134260 @default.
• W4324136145 hasConceptScore W4324136145C2779984678 @default.
• W4324136145 hasConceptScore W4324136145C2780073493 @default.
• W4324136145 hasConceptScore W4324136145C2781197716 @default.
• W4324136145 hasConceptScore W4324136145C2781278892 @default.
• W4324136145 hasConceptScore W4324136145C2781335228 @default.
• W4324136145 hasConceptScore W4324136145C535046627 @default.
• W4324136145 hasConceptScore W4324136145C55493867 @default.
• W4324136145 hasConceptScore W4324136145C71924100 @default.
• W4324136145 hasConceptScore W4324136145C86803240 @default.
• W4324136145 hasConceptScore W4324136145C87355193 @default.
• W4324136145 hasIssue "6_suppl" @default.
• W4324136145 hasLocation W43241361451 @default.
• W4324136145 hasOpenAccess W4324136145 @default.
• W4324136145 hasPrimaryLocation W43241361451 @default.
• W4324136145 hasRelatedWork W1688081899 @default.
• W4324136145 hasRelatedWork W2028576442 @default.
• W4324136145 hasRelatedWork W2144031118 @default.
• W4324136145 hasRelatedWork W2945345930 @default.
• W4324136145 hasRelatedWork W2972396084 @default.
• W4324136145 hasRelatedWork W3141170855 @default.
• W4324136145 hasRelatedWork W3163179811 @default.
• W4324136145 hasRelatedWork W4225790409 @default.
• W4324136145 hasRelatedWork W4298129326 @default.

• next